<DOC>
	<DOC>NCT01981187</DOC>
	<brief_summary>The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study</brief_summary>
	<brief_title>LGX818 for Patients With BRAFV600 Mutated Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of melanoma and colorectal cancer (CRC)) or hematologic malignancies and is in need of treatment because of progression or relapse. Patient's tumor has been evaluated and preidentified as having a tumor with a BRAFV600 mutation at a CLIA certified laboratory. Patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission. Patient must have progressive and measurable disease per RECIST 1.1. or other appropriate hematological response criteria. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Patient has received prior treatment with LGX818. Patients with Central Nerve System (CNS) metastasis or leptomeningeal carcinomatosis. Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycinC) prior to starting study drug. Patients with acute or chronic pancreatitis. Patients with impaired cardiac function or clinically significant cardiac diseases. Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other nonmelanomatous skin cancer, or insitu carcinoma of the uterine cervix.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>